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Gene therapy with adeno-associated virus (AAV) has advanced in the last few years from promising results in
animal models to >100 clinical trials (reported or under way). While vector availability was a substantial hurdle a
decade ago, innovative new production methods now routinely match the scale of AAV doses required for clinical
testing. These advances may become relevant to translational research in the chronic pain field. AAV for pain
targeting the peripheral nervous system was proven to be efficacious in rodent models several years ago, but has
not yet been tested in humans. The present review addresses the steps needed for translation of AAV for pain from
the bench to the bedside focusing on pre-clinical toxicology. We break the potential toxicities into three conceptual
categories of risk: First, risks related to the delivery procedure used to administer the vector. Second, risks related to
AAV biology, i.e., effects of the vector itself that may occur independently of the transgene. Third, risks related to
the effects of the therapeutic transgene. To identify potential toxicities, we consulted the existing evidence from
AAV gene therapy for other nervous system disorders (animal toxicology and human studies) and from the clinical
pharmacology of conventional analgesic drugs. Thereby, we identified required preclinical studies and charted a
hypothetical path towards a future phase I/II clinical trial in the oncology-palliative care setting.
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Unrelieved chronic pain is a critical health problem in
the US and worldwide. A report by the Institute of
Medicine estimated that 116 million Americans suffer
from pain that persists for weeks to years, with resulting
annual costs exceeding $560 million [1]. Pain is an espe-
cially common problem in patients with advanced can-
cer, with some studies reporting that the majority of
patients dying from metastatic solid tumors experience
severe unrelieved pain despite treatment with available
analgesics [2,3]. Antineoplastic treatment options have
often been exhausted for these patients, placing palli-
ation of symptoms at the center of treatment goals for
the limited remaining life span, typically weeks to a few
months. The combination of the great need for pain* Correspondence: beutler.andreas@mayo.edu
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unless otherwise stated.relief and of the presence of an underlying incurable dis-
ease creates scenarios for early clinical testing of the
most novel (and potentially risky) new pain treatment
strategies, first in selected patients with cancer pain as a
phase I clinical trial. Therefore, the subsequent review
on clinical translation and preclinical toxicology studies
is predicated on a future plan to translate AAV gene
therapy first in the palliative oncology setting.
Two vector systems have been most extensively stud-
ied in gene therapy for pain: Herpes simplex virus
(HSV), which has already been tested in cancer pain pa-
tients [4]; and adeno-associated virus (AAV). AAV, the
subject of this review, has not been tested clinically for
pain. However, AAV is arguably the most advanced and
widely studied vector in terms of clinical trials seeking
long-term gene expression in non-malignant tissues [5].
The first AAV therapeutic product, alipogene tiparvovec,
is now marketed in Europe [6]. Therefore, substantial
pre-clinical toxicology data and clinical phase I/IIl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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able to the translational development of this vector in
the field of pain.
Defining the scope of possible toxicities
The potential toxicities of AAV for pain can be concep-
tually broken down into mutually exclusive categories of
risk. This review divides toxicities as follows: the proced-
ure employed for vector delivery to the target tissue, i.e.,
a surgical/interventional risks (section 3); the AAV vec-
tor itself (sin transgene), i.e., viral and immune-biology
(section 4); and the specific therapeutic gene, i.e.,
pharmacology (section 5). An overview is provided as a
semantic “mind map” in Figure 1.
Potential toxicities related to the procedure
employed for vector delivery
Two routes of delivery have been used in rodent models
to demonstrate analgesic efficacy of AAV through gene
transfer to the nociceptive neurons in the DRG: intra-
thecal (IT) or intraganglionic (IG) administration.
The IT route delivers the vector to the cerebrospinal
fluid (CSF) and has been achieved in rats by inserting an
IT catheter through the cisterna magna and advancing it
caudally to the lumbar level [7-10]. The same approachFigure 1 Potential toxicities of adeno-associated virus (AAV) gene the
categories (blue). For each type of risk existing evidence is highlighted (red) a
MTD, maximum tolerated dose; CNS, central nervous system; IG, intraganglion
IL-10, interleukin-10.has been used in dogs [11,12]. In pigs, we recently re-
ported an alternative: direct injection into the lumbar
CSF by a lateral lumbar puncture under interventional
image guidance with a computed tomography (CT)
scanner [13]. In humans, IT delivery can be easily per-
formed by lumbar puncture (LP), a routine bedside pro-
cedure with excellent safety profile [14].
Therefore, no additional toxicity studies would be
needed in regards to the LP procedure risk, if a phase I
trial of AAV for pain were to test vector administration
by the IT route.
The IG route delivers AAV directly into the DRG par-
enchyma. IG studies in rats accessed the DRG by an
open neurosurgical procedure [15-19], which would not
be attractive in humans because it would require a com-
plicated and invasive procedure. We therefore developed
a minimally invasive, CT imaging-guided technique to
safely target the DRG in the pig model. Using a custom-
ized needle assemble for convection enhanced delivery
(CED), we then demonstrated efficacy of CED to deliver
AAV into the DRG parenchyma [20]. Comparative anat-
omy analysis of the human and the porcine spine sug-
gested that the technique will be easily translatable to
humans. As a matter of fact, the imaging equipment
used in our study was identical with the state-of-the artrapy for chronic pain. Risks were sorted into three mutually exclusive
nd future studies towards pre-clinical toxicology are proposed (green).
ic; IT, intrathecal; DRG, dorsal root ganglia; ppßE, prepro-ß-endorphin;
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terventions in humans.
In the field of interventional neuroradiology, it is com-
mon practice to target small structures such as the DRG
for drug injections or biopsy. Ultrasound ablation of the
spinal sensory nerve root has also been reported [21].
Therefore, while IG drug delivery is a new clinical pro-
cedure, it will resemble clinical practice of similar inter-
ventions. Accordingly, we conclude that only a limited
scope of additional preclinical toxicity assessment of the
IG injection procedure might be needed, e.g., to deter-
mine absence of DRG tissue damage, and that such
studies can be performed in the pig model of the pro-
cedure that we have already in place.
Potential toxicities associated with the AAV
vector: Viral- and immune biology
Clinical translation of AAV for pain faces the issue of
general vector toxicity: the risk of AAV itself (without
the transgene, which will be discussed in the Section 4
below). This section is predicated on the conservative
assumption that vector may spread systemically to all
organ sites, even though the IT and IG route of adminis-
tration attempts to limit such spread.
Previous experience with AAV gene therapy identified
several mechanisms by which the vectors trigger an ad-
verse reaction; each is addressed in a separate subsection
below.
Vector related general toxicities: insertional mutagenesis,
germ line transmission, and replication escape
AAV vectors persist in cells in two states, as episomal
concatamers and, for a small minority of vector copies,
chromosomal integration [22]. In a specific experimental
setting of newborn mice, AAV vectors were found to in-
tegrate into the genomes of hepatocytes at a rate of
0.1 – 1% of transduction events [23,24] resulting in the
development of hepatocellular carcinoma [25]. While
this report generated substantial concern in the field,
subsequent investigation by numerous laboratories have
suggested that the observation is likely not applicable to
AAV gene therapy in adult humans. No evidence of in-
sertional mutagenesis was reported after systemic deliv-
ery of AAV in humans or large animals models or after
selective delivery to the CNS in any species.
Transmission to the germ line has not been found in
any AAV clinical trial. While AAV particles were de-
tected in the semen of subjects receiving AAV2 into the
hepatic artery [26], this was temporary.
The potential of replication escape of the recombinant
AAV was shown in vitro in the setting of co-infection
with the wild type AAV2 and a helper virus [27]. How-
ever, it has not been reported in any of the AAV preclin-
ical toxicology studies or subsequent clinical trials.The most serious adverse event in the setting of a
AAV human trial occurred in 2007 when a patient died
22 days after receiving intra-articular AAV encoding
etanercept, a tumor necrosis factor receptor blocker
[28,29], from a large retroperitoneal hematoma and
systemic histoplasmosis. The FDA stopped the clinical
trial but, after an investigation, allowed the trial to re-
sume. Similar adverse events were not seen in any of
the other patients.
In regards to AAV for pain, the above evidence sug-
gests that issues of insertional mutagenesis, germ line
transmission, replication escape, and dissemination of
the vector to the public domain, have been so thor-
oughly addressed in the field. The adverse event in the
AAV-etanercept trial suggests that in the case of IL-
10, a transgene that is similar to etanercept in regards
to its immune-suppressive effect, measurement of sys-
temic levels should be an important goal of preclin-
ical toxicity assessments. Furthermore, a pain trial in
patient with incurable cancer could answer some of
the above questions in humans, at least if (some of
the) patients may decide that after their (at trial entry
anticipated) death from cancer (i.e., at the end of the
trial) autopsy tissue may be sampled for research
purposes.Immune response to the AAV vector (sin transgene)
AAV for pain by the IT or IG route will trigger a sero-
logical immune response to the vector capsid. In addition,
cellular immunity to the vector capsid has to be carefully
considered, although (or because) fewer predictions may
be possible in regards to the cellular immunity one may
anticipate in humans.Serological immunity
AAV delivered IT or by direct infusion into the brain
parenchyma led to >100-fold increase in the titer of cir-
culating NAb in large animal models as shown for
AAV2 [30,31], AAV1 [32], AAVrh10 [33], and AAV9
[34,35]. The measured titers of circulating NAb seemed
to be proportionate to the total dose of AAV vector ad-
ministered. The clinical trials employing intraparenchy-
mal infusion of AAV to the brain also demonstrated a
rise of circulating NAb in some but not all patients
[36-42]. NAb titers in the CSF were examined only in
some of these studies. When measured, the CSF NAb
levels were consistently lower compared to the sys-
temic NAb, suggesting the systemic origin of the
humoral immune response. Importantly, while NAb
occur, they have no pathological consequence: No
clinical symptoms or adverse effects were associated
with the presence of NAb in any animal or human
study.
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AAV transduction when the vector is delivered systemic-
ally [43]. In regards to IT AAV, studies in large animal
models suggest a threshold effect for the capacity of sys-
temic NAb to prevent AAV transduction. In non-
human NHP, transduction by IT AAV9 was inhibited
by NAb titer of ≥ 1:200 but not affected by titers of ≤
1:128 [35,44]. Studies in dogs performed by Haurigot
et al. [34] demonstrated only moderately reduced
CNS- and PNS transduction rates for NAb titers as
high as 1:1000, suggesting that an immune privilege-
like status may apply to the PNS. Pre-existing sys-
temic NAb did not affect intraparenchymal gene
transfer to the brain by any serotype in either NHP
[31] or humans [41].
For the development of AAV for pain, we conclude
that the vector will induce NAb without any pathological
consequences. Pre-existing NAb may diminish IT trans-
duction rates, but the extent or threshold is a clinical re-
search question (of minor importance) that may be
answered in a clinical trial. Pre-existing NAb will not
affect IG delivery of AAV. Taken together, we propose
that a phase I trial of AAV for pain should collect speci-
men to measure NAb before and after vector adminis-
tration, while no further preclinical studies are required
towards that plan. Preexisting NAb should not be an ex-
clusion criterion for individual patients considered for
IT or IG AAV for cancer pain.
Cellular immunity
The clinical significance of CD8 mediated cytotoxicity
directed against the AAV capsid and leading to a de-
struction of the transduced cells arose as an issue in
a clinical trial of AAV2 for hemophilia B [26]. Im-
portantly, the precedent preclinical studies had failed
to predict the cellular immune response in animal
models [45].
Subsequent animal and human studies demonstrated that
the extent of cellular immune response against AAV might
depend on the host species, the AAV serotype, and the tar-
get tissue. A comparison of rodents, large animal species,
and humans showed that humans are prone to mount a
cellular immune response to systemic AAV more readily
than other species [46,47]. The choice of AAV serotype
may affect the cellular immunity through direct, antigen
presenting cell-independent activation of T-lymphocytes by
an AAV capsid [48,49]. When compared to systemic ad-
ministration, delivery of AAV directly to the nervous sys-
tem did not result in cell-mediated immunity to the AAV
capsid for either the intraparenchymal route, tested in both
large animals and humans [32-34,36,41,42,50-56] or the IT
route, tested to date in large animals only [34,57,58].
Based on this evidence, the occurrence of a cellular
immune response against the AAV capsid in the PNScannot be definitely excluded on the basis of large ani-
mal studies. It will therefore be a critical focus of a phase
I clinical trial of AAV for pain, which will need to in-
clude collection of peripheral mononuclear blood cells
and extensive post-mortem histopathological analysis for
possible immune-toxicity. This approach appears par-
ticularly justified by the absence of cellular immunity-
associated adverse effects in the context of previous
AAV studies in the CNS. Furthermore, a cellular im-
mune response could be effectively managed by im-
munosuppression [36,49], suggesting that this option,
i.e., use of systemic corticosteroids, should be allowed in
a clinical trial of AAV for pain if immune toxicity, e.g., a
Guillain-Barre like syndrome is seen in a patient. In
addition, an AAV for pain human trial may provide
unique opportunities for insights into the cellular im-
munity against AAV in the nervous system, if collection
of post-mortem tissue can be accomplished.
AAV serotypes and off-target biodistribution
In order to avoid toxicities and facilitate clinical transla-
tion of AAV for pain, selection of AAV serotypes will
play a critical role. The ideal serotype for AAV for pain
would effectively transduce PNS neurons after IT or IG
administration; show low levels of escape to peripheral
organ sites; and have precedent safety data available
from a clinical trial (for another disease).
AAV8 effectively transduced the DRG neurons, while
showing limited brain penetration upon IT administration
in rodents [59-61], which might limit toxicities associated
with CNS transduction. However, AAV8 manifests strong
hepatotropism after systemic administration (and has thus
been a leading contender in the preclinical and clinical
studies of hemophilia B) [49]. While biodistribution of
IT AAV8 has not been examined in a large animal
model, any systemic spread of the vector would likely
lead to transduction of the liver, raising the issue of sys-
temic transgene effects.
IT AAV9 transduces both the PNS and CNS [34,35,
44,62,63] and is in the final stages of preclinical develop-
ment for mucopolysaccharidosis IIIA and giant axonal
neuropathy [34,58], with studies suggesting an excellent
safety profile for IT doses of up to 2 × 1013 genome cop-
ies (GC) in NHP (with projected dose of 3.5 × 1013 GC
in humans). Widespread CNS transduction may be a
characteristic of AAV9 and may appear less attractive
for gene therapy for pain, at least for the current ap-
proaches that specifically target the PNS and spinal cord.
AAV9 has also been reported to transduce the CNS after
intravascular delivery, suggesting the ability of this sero-
type to cross the blood brain barrier (BBB) [43,44].
AAV2 and AAVrh10 are the only serotypes that have
been clinically tested in humans in the CNS. The safety
of intraparenchymal infusion of up to 1 × 1012 GC of
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of Canavan disease [64], late infantile neuronal ceroid
lipofuscinosis, LINCL [40], Parkinson disease [37,41,
65-67], and Alzheimer disease [54]. AAVrh10 showed
comparable safety for doses up to 7.2 × 1011 GC, while
achieving higher brain penetration after intraparenchymal
infusion compared to AAV2 [33] and was clinically tested
for mucopolysaccharidosis IIIA [36] and LINCL [68].
Recent advances in AAV biology showed promise in
developing AAV particles with improved transduction
efficiency or tissue tropism. The improved transduction
efficiency has been demonstrated by using self-comple-
mentary (sc-) AAV vectors [69] and while no sc-AAV
has so far been used in the CNS in humans, systemic
delivery of sc-AAV8 showed safety in the clinical trial
for hemophilia B [49]. The improved tissue tropism of
AAV has been achieved by rational capsid engineering
[70]. While most of these studies are in the early phases
of development, one of the novel serotypes termed
AAV2.5, selected for muscle tropism, has been brought
to a phase I clinical trial for Duchenne muscle dystrophy
[71]. IT administration of AAV2.5 in NHP resulted in
a transduction pattern similar to that of AAV9 [35],
making AAV2.5 an appealing alternative to AAV9 for
AAV for pain.
In regards to AAV for pain, we would arrive at differ-
ent conclusions for the two delivery routes under con-
sideration: IG administration of AAV2 or AAVrh10 as
well as IT administration of AAV9 might not need any
further investigations of serotype-specific toxicities and
might only need to be further assessed in regards to the
toxicities of a delivered therapeutic gene (as detailed in
Section 5 below). IT AAV8 requires further biodistribu-
tion studies to confirm whether its feasible characteris-
tics observed rodents also apply to large animals, which
will then determine whether AAV9 or AAV8 would the
vector of choice for the IT route in the clinics.
Potential toxicities associated with the
therapeutic genes: Pharmacology
In this section, the review will focus on two transgenes
that appear particularly promising for translating AAV
gene therapy for pain: prepro-ß-endorphin (ppßE) and
interleukin-10 (IL-10). The therapeutic efficacies of these
two genes have been investigated and validated in mul-
tiple vector systems including AAV by several independ-
ent groups including ours [61,72-74]. The ppßE gene
was originally developed by us for the use in pain gene
therapy [75]. A number of other analgesic genes have
been reported in a variety of vector systems and might
be alternative candidates for the clinical translation of
AAV for pain, whereby the pharmacological assessment
will follow similar principles as laid out here for ppßE
and IL-10.Dose–response relationship and therapeutic index:
Transgene as a drug
Effects of the transgene products can be assessed by ap-
plying the principles established in pain pharmacology
for conventional (non-gene therapy) drugs. Most anal-
gesic drugs, including the peptide ß-endorphin (ßE, con-
sidered as a gene-encoded version here), show dose
dependence in regards to both their analgesic- and toxic
effect. Low doses of analgesic drugs thereby exert low (if
any) pharmacological effect and dose escalation results
in an analgesic effect and eventually, if doses exceed a
certain threshold, the gradual emergence of toxicity. The
drug level needed to produce the toxic effect relative to
a therapeutic effect is the therapeutic index.
The emphasis on the dose–response relationship and
the therapeutic index in pain pharmacology provides im-
portant guidance in regards to the development of AAV
for pain. A certain degree of toxicity may be expected at
high-therapeutic doses and may be not only acceptable
but even the goal of dose-escalation in order to optimize
the therapeutic benefit. The rationale for delivering the
ppßE gene by AAV is the expectation of a favorable
therapeutic index. The basis for its safe development will
be the appropriate choice of the initial vector dose in a
phase I/II trial.
Tissue-specific transgene expression: improving the
therapeutic index
Conventional analgesic drugs, such as opioids, adminis-
tered orally or intravenously expose all sites of the body
to similar drug concentrations. In contrast, AAV gene
therapy for pain by the IT or IG route aims at targeting
anatomical sites known to mediate analgesic efficacy of
opioids but not toxicity: the spinal compartment of the
nervous system including the DRGs and the posterior
horn of the spinal cord.
IT delivery improves the therapeutic index of conven-
tional opioids. This principle is firmly established
through animal studies [11,12] and the use of IT pump-
mediated delivery of opioids in patients with the most
severe pain states [76]. Vector systems that were initially
used in gene therapy for pain, such as adenovirus [77,78]
or plasmids [74,79] transduced only meningeal lining fi-
broblasts, which secreted the transgene product into the
spinal CSF emulating an IT pump.
An important observation in the field of AAV for
pain, however, has been the marked tropism of AAV
for DRG neurons if administered IT or IG. This was a
very favorable, while unexpected, finding and has sub-
sequently been confirmed by several groups in differ-
ent animal models [16,18,59-61,80-82]. It has an
important promising implication for the pharmacology
of AAV for pain: the potential to not only match the
therapeutic index of IT opioids but to improve further
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can be formalized as follows. If the transgene encodes a
secreted protein such as ppßE and IL-10, the protein
can reach the target cells by two routes: (i) through
release into the CSF, i.e., emulating an IT pump, and
(ii) in an autocrine/paracrine fashion within the imme-
diate surrounding of the transduced cells. While the
ratio of biological effects (ii)/(i) cannot be directly
measured in animal models, it may be an important
consideration when assessing the viability of AAV gene
therapy for pain explicating why the therapeutic index
of AAV will likely be improved not only over systemic
opioids but also when compared with IT pump delivery
of opioids.
Of note, a high degree of DRG-neuron selectivity has
been the fundamental rationale for the HSV-based ap-
proach to pain gene therapy by the subcutaneous route
of vector administration [4,83]. IT AAV may be less se-
lective for DRG neurons than subcutaneous HSV, but
will likely improve the therapeutic index over IT delivery
of conventional opioids (as discussed above). Further-
more, the IG route will very likely yield the most DRG
neuron-selective transgene activity achievable with AAV
potentially matching the DRG neuron-selectivity of sub-
cutaneous HSV.
Specific consideration for ppßE
ßE, the secreted peptide product of ppßE, is a μ-opioid
receptor agonist and thereby shares its pharmacological
activity with the most commonly used conventional opi-
oids such as morphine. The toxicological assessment of
ppßE can therefore be guided by the robust clinical ex-
perience with exogenous opioids. In addition, ßE was
tested in clinical trials.
The principal sites where opioid toxicity occurs at high
doses are the CNS and the periphery. The most com-
mon adverse effects of opioids in the CNS are nausea
and vomiting, mental status changes, pruritus, urinary
retention, and respiratory depression [84-87], while the
peripheral adverse effects include constipation, cardio-
vascular adverse events, derangement of hypothalamo-
pituitary axis, and immune-modulation [87-91]. Both the
CNS and peripheral adverse effects are dependent on
the drug concentration at a given site and may be re-
versed by naloxone, a μ-, κ-, and δ-opioid receptor
antagonist.
When IT administration of ß-endorphin was tested
in humans, it resulted in profound analgesia similar
to that attainable with exogenous opioids [92-97].
Dose escalation led to a toxicity profile that would be
expected with an IT opioid drug, whereby doses of
IT ßE of up to 7.5 mg resulted in miosis, drowsiness,
and elevation plasma prolactin levels in some pa-
tients. No systemic adverse effects related to thetreatment were found in those studies, reflecting the
inability of ß-endorphin to cross the BBB, keeping it
from escaping from the IT space to the systemic
circulation.
In conclusion, the therapeutic and toxic effects of
ppßE are expected to be vector dose-related and the
specific toxicities can be predicted from the previous
clinical experience with IT opioids and ßE. What re-
mains to be defined in the preclinical large animals
studies is the maximum tolerated dose (MTD) of the
vector encoding ppßE for both the IT and the IG route.
A phase I/II clinical would then test safety for vector
doses starting with the lowest potentially efficacious
dose and sequentially being escalated towards the MTD
established in animals.
Specific consideration for IL-10
IL-10 is of interest for pain therapy because it may be
the first/only available agent to target a mechanism of
chronic pain first described about a decade ago, glial ac-
tivation [98]. Recombinant IL-10 administered IT has
been found to be efficacious in animal models of
chronic pain [99,100]. The use of recombinant protein,
however, has not been tested in humans due to its short
half-life of IL-10 in the CSF, its inability to cross the
BBB, and the impracticality of continuous IT delivery
over a prolonged period of time [78]. A pharmaceutical
formulation of IL-10 needed for delivery by an IT pump,
i.e. the stability at ambient temperature and the high
concentration, has proved to be difficult. Therefore,
gene therapy may provide the best (or only) strategy for
testing targeted spinal delivery of IL-10 for pain in the
clinical setting.
While toxicity of IL-10 delivery targeted to the PNS by
either the IT or the IG route has not been addressed in
large animal models, rodent data suggest good tolerability
of IL-10 in the CSF [61,74,101,102]. Furthermore, sys-
temic toxicities of IL-10 have been thoroughly character-
ized in trials of recombinant IL-10 for Crohn disease,
rheumatoid arthritis, Wegener granulomatosis, and psori-
atic arthritis [103-107]. Safety studies showed that a single
intravenous injection of up 100 μg/kg IL-10 in healthy
humans led to transient, dose-related flu-like symptoms
accompanied by neutrophilia, monocytosis, lymphopenia,
and down-regulation of pro-inflammatory cytokines IL-1
and TNF-α [108]. Long-term intravenous or subcutaneous
administration of IL-10 in rats and NHP confirmed
hematological effects of IL-10 and also showed its inhibi-
tory effect on T-lymphocytes [109].
Establishing the MTD for AAV encoding IL-10 will be
an important goal for both the IT and the IG route.
Clinical testing would then start at a lower vector dose
with subsequent dose escalation to establish the MTD
in humans.
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Syngeneic transgenes will not induce serological or cellu-
lar immunity. Therefore, no immunity is to be expected in
a clinical trial using human IL-10 as therapeutic gene
and no special studies appear to be necessary towards
assessing it.
The case of ppβE may require additional consideration,
because the gene includes an artificial fusion site. Specific-
ally, the pre-pro sequence of ppβE (the amino-terminal
“pp” part of the protein) is taken from nerve growth factor
(NGF); thus, this portion of the gene by itself is not of
concern because it can be made syngeneic (by taking the
pre-pro sequence from human NGF). The carboxy ter-
minal portion of ppβE gene encodes the pharmacologic-
ally active βE peptide. By itself this portion of the gene is
not of concern either, because it can also be made syngen-
eic (by using the βE sequence as it occurs in the precursor
protein human pro-opiomelanocortin (POMC)). In the
ppβE gene, these two syngeneic peptides are fused creat-
ing a potentially non-syngeneic epitope.
The rationale for using ppβE rather than POMC is to
circumvent the requirement of POMC to be processed
in acidified secretory vesicles found only in certain cell
types and its reliance on the regulated secretory path-
way. ppβE can be processed into βE by all cell types and
secretion of βE occurs via the constitutive secretory
pathway yielding continuous release of the pharmaco-
logically active βE peptide, which is the desired property
of this therapeutic gene. Because the processing of the
ppβE peptide into its syngeneic components, the pre-
pro-sequence and βE, occurs immediately following its
ribosomal synthesis and co-translational transport into
the ER, the fusion epitope may not even have a chance
to become immunologically apparent. Therefore, to
evaluate the possibility of cellular immune toxicity, pre-
clinical toxicity studies of ppβE will have to assess the
integrity of transduced tissues such as neuropathological
evaluation of DRG.
A challenge for pre-clinical toxicology assessments is
whether to perform animal testing with syngeneic trans-
genes, i.e., specifically adapted to the animal species
employed, or to perform testing of the human-type vec-
tor slated to be used in a clinical trial, i.e. xenogeneic
to the animal model. Xenogeneic transgenes are well-
tolerated in rodents, which express even the bacterial
EGFP gene long term. However, xenogeneic transgenes
induced immunity in large animals [32]. As a conse-
quence, an AAV vector encoding a species-specific, i.e.,
syngeneic transgene could be used for preclinical toxi-
cology studies of AAV for pain. The vector that is ultim-
ately used in the clinic could also be given to animals,
but the latter type of studies should be limited to effects
observable within approximately one week because all
later effects can be expected to be confounded by axenogeneic immune response that is an artifact of the
testing scenario and not applicable to the anticipated
scenario of a clinical trial.
Conclusions
Responsible and effective preclinical-to-clinical transla-
tion of AAV for pain represents a substantial scientific
and regulatory challenge. Yet, the goal appears to be
supported by two considerations: The growing clinical
research experience with AAV (for non-pain applica-
tions) and the need for innovative clinical research in
patients with intractable pain from incurable cancer.
The following two sections follow these two notions in
an attempt to turn our review findings into a proposed
action plan.
Preclinical toxicity assessment
Additional studies required
For the IT route of AAV delivery, preclinical animals
studies are needed to
 Establish the MTD of AAV vectors
◦ Assess health of animals clinically
◦ Neuropathological assessment of neural structures
such as the DRG
◦ Repeat independent experiments for each specific
vector design: transgene, serotype
◦ If MTD cannot be reached, document absence of
toxicity at a dose exceeding the highest
concentration anticipated in humans, e.g., if dose
range contemplated in humans is 1011 to 1013
GC, then test up to 1014 GC in a large animal
 Establish biodistribution
We propose that testing in large animals would be
more meaningful than testing in rodents, even if per-
formed in a significantly smaller number of animals, be-
cause a species such as the pig better resembles the
mechanical-anatomical and immunological characteris-
tics of humans than rats. We propose that testing for
the first transgene-capsid combination should be done
in two iterations: a long-term experiment (such as
3 months follow up) with the syngeneic transgene (such
as made for the pig) and a short-term experiment (such
as ten days) with the human transgene (that would be
xenogeneic in pigs). For subsequent assessments of other
transgene-vector combinations, it may be justified to
limit studies to the vector that is to be used in the clin-
ical trials expressing the human transgene version.
For the IG route of AAV delivery, additional preclin-
ical animal studies are needed to
 Confirm the safety of placing a CED needle into the
DRG for vector infusion
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Existing studies reviewed above have already addressed
the following issues:
 General vector related toxicities including
insertional mutagenesis, germ line transmission,
replication escape, and dissemination of the vector
to the public domain—AAV vector administration
per se appears non-hazardous
 Serologic response against AAV (sin transgene)
Issues outside the realms of animal models
Modeling human immunity to vectors in animal models
has remained challenging and uncertain. While numer-
ous experimental approaches and assays have been used
or proposed, predictions from rodents appear to be
misleading if applied to humans and predictions from
various large animal models uncertain at best. The
conservative assumption therefore has to be that im-
mune toxicity is an anticipated untoward effect requiring
close monitoring in the clinical setting to protect pa-
tients and learn more about AAV vector biology in the
clinical setting.
Hypothetical design of a phase I/II clinical trial
Most gene therapy trials for non-malignant disorders
have been conducted in patients with a near-normal life
expectancy, such as in the case of hemophilia B. The
clinical trial of AAV for pain that we envision would
substantially differ in terms of target population: Patients
with an unacceptably high symptom burden from in-
tractable pain at the end of life in the setting of a pro-
gressing cancer that is incurable or even untreatable (by
antineoplastic therapies). Enrollment requirements could
include a minimum- and a maximum life expectancy.
Both could be shorter for early patient cohorts to limit
the impact that unexpected adverse effects could have,
such as a range of 4 to 8 weeks. As safety is established
throughout the course of the trial, the minimum life ex-
pectancy could become longer, e.g., 3 months, to allow
collection of data on longer-term effects. While the same
high scientific standards should apply to a palliative-care
clinical trial in cancer patients as to trials in patients
with non-malignant diseases, the proposed clinical trial
setting may be the most appropriate for a pre-clinical to
clinical research transition in a case such as AAV gene
therapy, where toxicities cannot be modeled perfectly in
animals.
A phase I/II clinical trial would likely focus first on the
transgene with the best-known pharmacology, i.e., an
opioid. ppßE may therefore be the most suitable candi-
date for early clinical translation thanks to the extensive
clinical experience with exogenous IT opioids. In
addition, the spread of the vector suspension in the ITspace for a given volume can be guided by the experi-
ence with IT drugs such as methotrexate, which distrib-
ute within the CSF-filled space and are routine given as
in a volume of 5 cc and may be safe for injection vol-
umes of up to 10 ml in adults.
An exciting medium- to long-term impact of studying
AAV for pain in the cancer center setting may be the op-
portunity to gain insights into AAV biology in humans.
Given that some patients may consent to postmortem
tissue collection (an autopsy) a trial in this setting may
offer a unique chance for analyzing tissue samples from
human subjects receiving AAV at a markedly more rapid
turnaround than in previous AAV clinical trials.
Another long-term potential from the perspective of
analgesic treatment development is that AAV gene ther-
apy may serve as a platform for investigating novel anal-
gesic targets. For instance, the efficacy of IL-10 would
test the analgesic effects of counter-acting glial activa-
tion in the setting of the human pain state, which could
then guide development of conventional (small mol-
ecule) drugs harnessing the same mechanism of action.
While IL-10 has been proposed as an analgesic strategy
more than a decade ago, clinical testing could not be
performed to date presumably because prolonged IT de-
livery of recombinant IL-10 is impractical. AAV could be
the means to bring novel analgesic strategies such as IL-
10 from the laboratory into clinical trials.
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